LT2605652T - Diketonai ir hidroksiketonai kaip katenino signalinio kelio aktyvintojai - Google Patents

Diketonai ir hidroksiketonai kaip katenino signalinio kelio aktyvintojai

Info

Publication number
LT2605652T
LT2605652T LTEP11818727.7T LT11818727T LT2605652T LT 2605652 T LT2605652 T LT 2605652T LT 11818727 T LT11818727 T LT 11818727T LT 2605652 T LT2605652 T LT 2605652T
Authority
LT
Lithuania
Prior art keywords
hydroxyketones
diketones
signaling pathway
catenin signaling
pathway activators
Prior art date
Application number
LTEP11818727.7T
Other languages
English (en)
Inventor
Sunil Kumar Kc
David Mark WALLACE
John Hood
Charlene F. Barroga
Original Assignee
Samumed, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samumed, Llc filed Critical Samumed, Llc
Publication of LT2605652T publication Critical patent/LT2605652T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
    • C07C49/784—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic with all keto groups bound to a non-condensed ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
LTEP11818727.7T 2010-08-18 2011-08-17 Diketonai ir hidroksiketonai kaip katenino signalinio kelio aktyvintojai LT2605652T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37468710P 2010-08-18 2010-08-18
US201061427974P 2010-12-29 2010-12-29
PCT/US2011/048086 WO2012024404A1 (en) 2010-08-18 2011-08-17 Diketones and hydroxyketones as catenin signaling pathway activators

Publications (1)

Publication Number Publication Date
LT2605652T true LT2605652T (lt) 2018-03-12

Family

ID=45594555

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17193280.9T LT3311666T (lt) 2010-08-18 2011-08-17 Diketonai ir hidroksiketonai kaip katenino signalinio kelio aktyvatoriai
LTEP11818727.7T LT2605652T (lt) 2010-08-18 2011-08-17 Diketonai ir hidroksiketonai kaip katenino signalinio kelio aktyvintojai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP17193280.9T LT3311666T (lt) 2010-08-18 2011-08-17 Diketonai ir hidroksiketonai kaip katenino signalinio kelio aktyvatoriai

Country Status (22)

Country Link
US (9) US8609717B2 (lt)
EP (3) EP3311666B8 (lt)
JP (3) JP6086864B2 (lt)
CN (2) CN103153053B (lt)
AU (1) AU2011291989B2 (lt)
BR (1) BR112013003631B1 (lt)
CA (1) CA2807419C (lt)
CY (2) CY1120061T1 (lt)
DK (2) DK2605652T3 (lt)
ES (2) ES2879314T3 (lt)
HK (1) HK1254638A1 (lt)
HR (2) HRP20180196T1 (lt)
HU (2) HUE054810T2 (lt)
LT (2) LT3311666T (lt)
MX (2) MX340997B (lt)
NO (1) NO2605652T3 (lt)
PL (2) PL2605652T3 (lt)
PT (2) PT2605652T (lt)
RS (2) RS62051B1 (lt)
RU (2) RU2592694C2 (lt)
SI (2) SI2605652T1 (lt)
WO (1) WO2012024404A1 (lt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2297133B1 (en) 2008-06-25 2017-09-13 Forum Pharmaceuticals Inc. 1, 2 disubstituted heterocyclic compounds
DK2427454T3 (da) * 2009-05-07 2013-06-17 Envivo Pharmaceuticals Inc Heterocykliske phenoxymethylforbindelser
CN102595900B (zh) 2009-08-10 2015-07-15 萨穆梅德有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
US8609717B2 (en) 2010-08-18 2013-12-17 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators
US20140037599A1 (en) * 2012-08-03 2014-02-06 The Trustees Of The University Of Pennsylvania Compositions and Methods of Treating T Cell Deficiency
BR112015020391B1 (pt) 2013-02-22 2022-07-26 Samumed, Llc Gama-dicetonas como ativadoras da via de sinalização de wnt/beta-catenina
DK3206686T3 (da) 2014-08-20 2019-12-16 Samumed Llc Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
CA3030252A1 (en) * 2016-07-19 2018-01-25 Accellta Ltd. Culture media for culturing pluripotent stem cells in suspension
AU2017386417B2 (en) 2016-12-30 2022-07-14 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
EP3837351A1 (en) 2018-08-17 2021-06-23 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
WO2020245845A1 (en) * 2019-06-06 2020-12-10 Fermenta Biotech Limited An improved process to synthesize 5-(3-pyridyl)-2,2'-bithiophene(sensitizer)

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3040054A (en) 1960-08-03 1962-06-19 Olin Mathieson 2, 2'-(1, 4-diaminotetramethylene) bis(4-thiazolecarboxylic acid), salts and process
SU335946A1 (ru) * 1971-01-06 1977-04-05 Вильнюсский государственный университет им.В.Капсукаса Способ получени 5-( -алкиламиноациламино)-бензодиоксанов-1,4
US3855675A (en) 1971-05-25 1974-12-24 Squibb & Sons Inc 1-(2-furanylmethyl)-1h-pyrazolo(3,4-b)pyridine-5-methanones
US4014889A (en) * 1972-12-20 1977-03-29 Bayer Aktiengesellschaft Process for preparing ketones
DE2262343A1 (de) * 1972-12-20 1974-06-27 Bayer Ag Verfahren zur herstellung von ketonen
US4032526A (en) * 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
DE3331692A1 (de) 1983-09-02 1985-03-28 Basf Ag, 6700 Ludwigshafen 3-phenyl-4-methoxycarbonylpyrazole, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
EP0230110A1 (en) 1985-11-30 1987-07-29 FISONS plc Pharmacologically active pyrrole and pyrazole derivatives
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
WO1990011366A1 (en) 1989-03-28 1990-10-04 Genetics Institute, Inc. Osteoinductive compositions
JPH01501791A (ja) 1986-11-19 1989-06-22 ケメックス　ファーマシューティカルズ，インコーポレイティド 薬理学的に活性な化合物およびそれらの混合物、有機組成物および金属塩類
NZ227287A (en) 1987-12-21 1992-01-29 Merck & Co Inc 2,5-diaryl tetrahydrofurans and medicaments
AU626881B2 (en) 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
EP0365089A3 (en) 1988-10-18 1991-06-05 Merck & Co. Inc. 2-aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl) tetrahydrothiophen and analogs
EP0454204B1 (en) * 1990-04-27 1995-06-28 Duphar International Research B.V Method for the photochemical isomeration of organic compounds under the influence of a photosensitizer
DE4104931A1 (de) 1991-02-18 1992-08-20 Hoechst Ag Verfahren zur herstellung substituierter indene
JPH05170764A (ja) * 1991-12-24 1993-07-09 Sumitomo Pharmaceut Co Ltd 新規なヒドロキシカルコン誘導体
GB9203806D0 (en) 1992-02-21 1992-04-08 Unilever Plc Sunscreen agents
DK57892D0 (da) 1992-05-01 1992-05-01 Nkt Res Center As Fremgangsmaade til fremstilling af 1,4-bis-aryl-butan-1,4-dioner og poly(arylen-butan-1,4-dioner)
WO1996011180A1 (fr) * 1994-10-07 1996-04-18 Meiji Seika Kabushiki Kaisha COMPOSE η-DICETONE POSSEDANT UN EFFET INHIBITEUR DE L'AGREGATION PLAQUETTAIRE
AU1726695A (en) 1995-01-13 1996-07-31 Board Of Regents, The University Of Texas System Turcasarins, novel expanded porphyrins, and uses thereof
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
US5585118A (en) 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
US5668165A (en) 1995-06-07 1997-09-16 Scriptgen Pharmaceuticals, Inc. Small molecule inhibition of RNA/ligand binding
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
CA2246725A1 (en) 1996-02-19 1997-08-21 Japan Tobacco Inc. Therapeutic agent for diabetes
US6620804B2 (en) 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
EP1021178B1 (en) 1996-06-03 2003-08-27 Purdue Research Foundation Selenophene anti-tumor agents
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
KR20010071975A (ko) * 1998-08-11 2001-07-31 해슬러 요세 살선충성 피라졸
WO2000026197A1 (en) 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Novel inhibitors of impdh enzyme
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
EP1196384A4 (en) * 1999-06-25 2002-10-23 Merck & Co Inc 1- (AROMATIC OR HETEROAROMATICALLY SUBSTITUTED) -3- (HETEROAROMATICALLY SUBSTITUTED) -1,3-PROPANDIONS AND THEIR APPLICATIONS
ATE340265T1 (de) 1999-07-09 2006-10-15 Forschungszentrum Juelich Gmbh Verfahren zur reduktion von ketogruppen enthaltende verbindungen
WO2001004100A1 (en) 1999-07-13 2001-01-18 Lonza Ag Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
DE60019505T2 (de) * 1999-08-06 2005-09-15 Ciba Speciality Chemicals Holding Inc. Mikrobizide Wirksubstanzen
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
EP1224189B1 (en) 1999-10-07 2006-01-25 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
US6268375B1 (en) 1999-12-29 2001-07-31 Research Triangle Institute 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2001294581A (ja) 2000-04-12 2001-10-23 Nippon Bayer Agrochem Co Ltd イソチアゾール誘導体
US6794362B1 (en) 2000-05-30 2004-09-21 Connective Tissue Imagineering Llc Asparagine containing elastin peptide analogs
AU2001271022B2 (en) 2000-07-05 2006-08-17 Astellas Pharma Inc. Propane-1,3-dione derivatives
DE10059749A1 (de) 2000-12-01 2002-06-20 Henkel Kgaa Fixierung von Wirkstoffen an fasrigen Materialien
US7012075B2 (en) 2001-03-02 2006-03-14 Merck & Co., Inc. Cathepsin cysteine protease inhibitors
ES2292753T4 (es) 2001-03-29 2009-02-16 Vertex Pharmaceuticals Incorporated Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
EP1435957B1 (en) 2001-04-30 2009-06-17 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
WO2003016266A1 (en) 2001-08-16 2003-02-27 Japan Tobacco Inc. β-KETOAMIDE COMPOUNDS AND MEDICINAL USE THEREOF
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
IL160964A0 (en) 2001-10-11 2004-08-31 Kaneka Corp Peroxisome proliferator activated receptor ligand and process for producing the same
CN1155590C (zh) * 2002-04-12 2004-06-30 中国药科大学 具有抗肿瘤活性的色酮类化合物及其开环产物与制备方法
EP1534680B1 (en) * 2002-08-14 2012-02-22 Pharmaco Investments, Inc. Prenylation inhibitors and methods of their synthesis and use
US20040266732A1 (en) 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
FR2849598B1 (fr) 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US20040224003A1 (en) 2003-02-07 2004-11-11 Schultz Robert K. Drug formulations for coating medical devices
CA2527170A1 (en) 2003-04-15 2004-10-28 Astrazeneca Ab Therapeutic compounds
AU2004259738B2 (en) 2003-07-17 2011-11-17 Plexxikon, Inc. PPAR active compounds
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
US20060276536A1 (en) 2004-02-12 2006-12-07 Vander Jagt David L Cancer treatment using curcumin derivatives
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
ZA200609924B (en) 2004-05-06 2008-12-31 Univ California Substituted enaminones, their derivatives and uses thereof
EP1752452A4 (en) * 2004-06-04 2010-07-14 Astellas Pharma Inc DERIVATIVE OF PROPANE-1, 3-DIONE OR ITS SALT
DE102004029309A1 (de) 2004-06-17 2005-12-29 Bayer Cropscience Gmbh Pyridinylisoxazole und ihre Verwendung als Herbizide
CA2584493A1 (en) * 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
US7915255B2 (en) 2004-08-16 2011-03-29 Verva Pharmaceuticals Pty Ltd Metabolism-modulating agents and uses therefor
FR2880802B1 (fr) 2005-01-14 2008-12-19 Sederma Soc Par Actions Simpli Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
US20060264897A1 (en) 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
BRPI0607094A2 (pt) 2005-02-01 2009-08-04 Wyeth Corp composto da fórmula i; uso do composto para o tratamento de uma doença ou distúrbio associado à atividade excessiva de bace em um paciente que dele necessita; uso do composto para modular a atividade de bace; e composição farmacêutica
KR101046039B1 (ko) 2005-03-31 2011-07-01 아스텔라스세이야쿠 가부시키가이샤 프로판-1,3-디온 유도체 또는 그의 염
US8178727B2 (en) 2005-06-27 2012-05-15 National University Corporation Tohoku University Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer
DE102005031580A1 (de) * 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
AU2006275514B2 (en) 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
EP1954274B8 (en) 2005-11-10 2011-01-12 ChemoCentryx, Inc. Substituted quinolones and methods of use
WO2007103584A2 (en) 2006-03-09 2007-09-13 Nanovir, Llc Polyamides for treating human papilloma virus
US8841483B2 (en) 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
JP2008007428A (ja) 2006-06-27 2008-01-17 Showa Denko Kk 皮膚外用シワ防止剤
WO2008020625A1 (fr) 2006-08-17 2008-02-21 Kanazawa University Composé de dibenzoylméthane et composition pharmaceutique contenant le composé en tant qu'ingrédient actif
WO2008026318A1 (en) 2006-08-30 2008-03-06 Kabushiki Kaisha Yakult Honsha Anti-wrinkle agent
US7875603B2 (en) 2006-09-21 2011-01-25 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
JP5207341B2 (ja) 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
JP5231829B2 (ja) * 2007-02-15 2013-07-10 石原産業株式会社 ピリジル−トリアゾロピリミジン誘導体又はその塩、それらを含有する有害生物防除剤並びにそれらの製造方法
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
JP5309318B2 (ja) 2007-03-09 2013-10-09 国立大学法人 岡山大学 エステル、カルボン酸及びアミドの製造方法
KR101404398B1 (ko) 2007-06-20 2014-06-09 (주)뉴트리 주름개선 화장료 조성물
PL2567709T3 (pl) 2007-11-02 2018-06-29 Novartis Ag Cząsteczki i sposoby modulowania białka związanego z receptorem dla lipoproteiny o niskiej gęstości 6 (LRP6)
EA201000673A1 (ru) 2007-11-05 2011-04-29 Новартис Аг СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
EP2240276B1 (en) 2007-12-06 2020-12-02 Centre National de la Recherche Scientifique (CNRS) Iron and copper catalytic systems for cross-coupling reactions
JP2009179619A (ja) * 2008-02-01 2009-08-13 Toyo Ink Mfg Co Ltd 新規オキシムエステル化合物およびそれを含んでなるラジカル重合開始剤および重合性組成物
CN102099005A (zh) * 2008-02-27 2011-06-15 先灵-普劳健康护理产品公司 含有阿伏苯宗的防晒组合物增强的光稳定性
EP2428504B1 (en) 2008-04-14 2017-05-17 The Board of Regents of the University of Texas System Small molecule inhibitors of the pleckstrin homology domain and method for using same
WO2009136889A1 (en) 2008-05-08 2009-11-12 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
CN102271668B (zh) 2008-11-05 2015-01-07 南加州大学 表观遗传调控的小分子调节剂和其治疗应用
US20130039998A1 (en) * 2008-12-24 2013-02-14 University Of Washington Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
JP5246715B2 (ja) 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2011009826A2 (en) 2009-07-21 2011-01-27 ADAMED Sp.z o.o. Novel chalcone derivatives with cytotoxic activity
US8609717B2 (en) 2010-08-18 2013-12-17 Samumed, Llc β- and γ-diketones and γ-hydroxyketones as WNT/β-catenin signaling pathway activators
KR101784940B1 (ko) 2010-08-31 2017-10-12 (주)아모레퍼시픽 피부 탄력 개선용 화장료 조성물
EP2670733B1 (en) 2011-02-01 2019-04-10 The Board of Trustees of the University of Illionis N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same
US8871748B2 (en) 2011-09-07 2014-10-28 Island Kinetics Inc. Retinal cyclodextrin acetals and hemiacetals for treating skin complexion disorder
US9668691B2 (en) 2011-09-22 2017-06-06 Lvmh Recherche Method to measure skin elasticity and firmness
PL2810198T3 (pl) 2012-01-30 2024-01-22 Universiteit Gent Związki przeciwinwazyjne
US20130302381A1 (en) 2012-05-09 2013-11-14 Cook Medical Technologies Llc Implantable Medical Devices Including a Water-Insoluble Therapeutic Agent
US8865700B2 (en) 2012-12-20 2014-10-21 Avon Products, Inc. Collagen stimulators and their use in the treatment of skin
BR112015020391B1 (pt) 2013-02-22 2022-07-26 Samumed, Llc Gama-dicetonas como ativadoras da via de sinalização de wnt/beta-catenina
EP2958903B1 (en) 2013-02-22 2017-04-12 H. Lundbeck A/S Vortioxetine manufacturing process
HUE037192T2 (hu) 2013-02-22 2018-08-28 Pfizer Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai
ME03394B (me) 2013-02-22 2020-01-20 Medimmune Ltd Antidllз-antitelo-pbd konjugati i nihovа upotreba
DK3206686T3 (da) 2014-08-20 2019-12-16 Samumed Llc Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker

Also Published As

Publication number Publication date
US10314832B2 (en) 2019-06-11
JP6407361B2 (ja) 2018-10-17
EP3915367A1 (en) 2021-12-01
US20120046320A1 (en) 2012-02-23
JP2017048192A (ja) 2017-03-09
BR112013003631A2 (pt) 2016-08-30
CN103153053A (zh) 2013-06-12
PL2605652T3 (pl) 2018-04-30
US20140080902A1 (en) 2014-03-20
US8629176B1 (en) 2014-01-14
HRP20210955T1 (hr) 2021-09-03
JP2017165773A (ja) 2017-09-21
AU2011291989B2 (en) 2015-08-20
CA2807419A1 (en) 2012-02-23
PL3311666T3 (pl) 2021-11-08
US8609717B2 (en) 2013-12-17
CY1120061T1 (el) 2018-12-12
RU2016124136A (ru) 2018-12-03
JP6162306B2 (ja) 2017-07-12
EP3311666B1 (en) 2021-05-05
CA2807419C (en) 2019-09-24
US20210353604A1 (en) 2021-11-18
US9884053B2 (en) 2018-02-06
ES2652363T3 (es) 2018-02-01
HUE036240T2 (hu) 2018-06-28
SI3311666T1 (sl) 2021-09-30
MX2013001940A (es) 2013-06-28
US8921413B2 (en) 2014-12-30
JP2013535515A (ja) 2013-09-12
RS62051B1 (sr) 2021-07-30
MX340997B (es) 2016-08-03
CN104672202A (zh) 2015-06-03
BR112013003631A8 (pt) 2017-12-26
PT2605652T (pt) 2018-01-08
PT3311666T (pt) 2021-06-21
RU2592694C2 (ru) 2016-07-27
EP2605652B1 (en) 2017-11-08
EP2605652A4 (en) 2014-02-19
AU2011291989A1 (en) 2013-03-07
RU2013111835A (ru) 2014-09-27
US20180333400A1 (en) 2018-11-22
DK2605652T3 (en) 2018-02-05
CY1124466T1 (el) 2022-07-22
US20150299157A1 (en) 2015-10-22
US20200121663A1 (en) 2020-04-23
EP3311666B8 (en) 2021-06-23
US20140005228A1 (en) 2014-01-02
LT3311666T (lt) 2021-07-12
HRP20180196T1 (hr) 2018-03-09
HUE054810T2 (hu) 2021-09-28
US9303010B2 (en) 2016-04-05
EP2605652A1 (en) 2013-06-26
RS56855B1 (sr) 2018-04-30
SI2605652T1 (en) 2018-04-30
BR112013003631B1 (pt) 2021-10-13
HK1254638A1 (zh) 2019-07-26
DK3311666T3 (da) 2021-06-28
NO2605652T3 (lt) 2018-04-07
MX354133B (es) 2018-02-14
CN104672202B (zh) 2017-07-28
CN103153053B (zh) 2015-02-18
ES2879314T3 (es) 2021-11-22
EP3311666A1 (en) 2018-04-25
US9493437B2 (en) 2016-11-15
US20170246154A1 (en) 2017-08-31
WO2012024404A1 (en) 2012-02-23
JP6086864B2 (ja) 2017-03-01
US20150299174A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
HK1254638A1 (zh) 作為聯蛋白信號通路激活劑的二酮與羥基酮
EP2585052A4 (en) CONTROLLED RELEASE COMPOSITIONS HAVING REDUCED FOOD EFFECT
IL226496A0 (en) Watermelon plants produce dual-purpose pollen
EP2523927A4 (en) MAGNETO-CALORIC MATERIALS
EP2545563A4 (en) MAGNETOCALORIC MATERIALS
ZA201300180B (en) Novel oligoester
EP2604441A4 (en) LIGHT-EMITTING MEDIUM
AU334250S (en) Kitchen cutting board - steel coloured case
EP2611291A4 (en) PERFUSIONSZUSAMMENSETZUNG
HK1148179A1 (en) Intelligent lunch-box
EP2604440A4 (en) LIGHT-EMITTING MEDIUM
EP2529166A4 (en) FRIDGE
SG10201503142SA (en) Hydroalkylation processes
TWM402991U (en) LED seal structure
GB201011264D0 (en) Food dicer
PT2514429T (pt) Antioxidante
HU3865U (en) Underpants with groin-holder
GB201000929D0 (en) Articles with lighting effect
AU334248S (en) Kitchen cutting board - silver coloured case
AU329771S (en) Led
GB201016629D0 (en) Colour underscore
GB201010208D0 (en) Novel article
GB201016218D0 (en) Coloured saver
GB201005410D0 (en) Colours and shapes
TWM389636U (en) Stamp with decoration